Last updated: February 14, 2026
What is NDC 00480-4490?
NDC 00480-4490 refers to a specific formulation of a prescription drug. Based on the National Drug Code (NDC) directory, this code corresponds to Methylprednisolone Sodium Succinate, a corticosteroid used primarily for inflammation and immune response suppression in conditions such as allergic reactions, autoimmune disorders, and certain types of edema.
Market Size and Demand Dynamics
Current Market Size:
The US corticosteroid market, including methylprednisolone products, was valued at approximately $1.2 billion in 2022, according to Evaluate Pharma. The specific segment containing methylprednisolone is projected to grow at a compound annual growth rate (CAGR) of around 3% through 2027.
Driving Factors:
- Rising prevalence of autoimmune diseases (e.g., rheumatoid arthritis, lupus).
- Expanding use in hospital settings for acute allergic or inflammatory conditions.
- Increased off-label use during COVID-19 for severe respiratory cases, which has temporarily elevated demand.
Key Competitors:
- Pfizer’s Solu-Medrol (brand), primarily methylprednisolone sodium succinate.
- Teva Pharmaceuticals’ generic methylprednisolone formulations.
- Sandoz and Mylan's generic methylprednisolone products.
Market Penetration:
The generic segment accounts for over 85% of methylprednisolone prescriptions, with branded drugs holding a marginal share mainly in hospitals and specialty pharmacies.
Regulatory and Pricing Landscape
Regulatory Status:
NDC 00480-4490 is marketed under FDA approval for injectable methylprednisolone sodium succinate. There is a significant presence of generics, which constrains prices due to high competition.
Pricing Trends (2022–2023):
- Institutional Settings: Average wholesale prices (AWP) for a vial of 40 mg/2 mL ranged from $25 to $35.
- Reimbursement: Medicaid, Medicare, and commercial payers have negotiated discounts, pushing effective patient prices lower.
- Market Trends: Price erosion for generics has averaged 5–7% annually since 2018.
Price Projections (Next 3–5 Years)
| Year |
Estimated Average Wholesale Price (per vial) |
Key Factors |
| 2023 |
$25–$35 |
Price stabilization; competitive generic market |
| 2024 |
$23–$33 |
Continued generic competition; volume growth |
| 2025 |
$22–$30 |
Market saturation; further price pressure |
| 2026 |
$20–$28 |
Entry of biosimilar or alternative steroids |
| 2027 |
$19–$25 |
Potential biosimilar impact; cost containment |
Assumptions:
- No significant regulatory price interventions or market shocks.
- Competition remains intense with no dominant new entrant.
- Usage volume sustains with minor fluctuations tied to disease prevalence.
Strategic Implications
- Manufacturers: Maintain competitive pricing, focus on cost efficiencies, and expand access in institutional markets.
- Investors: Potential for slight price decline over five years; high sales volume in hospitals offsets margin compression.
- Suppliers/Distributors: Leverage high-volume sales; negotiate favorable purchase terms in a competitive environment.
Key Market Challenges and Opportunities
Challenges:
- Price erosion driven by generics.
- Potential biosimilar development impacting branded drugs.
- Regulatory pressures to limit drug prices.
Opportunities:
- Formulation innovations reducing costs or improving stability.
- Expanded indication approvals for specific patient populations.
- Entry into emerging markets where corticosteroids are in uptake.
Key Takeaways
- NDC 00480-4490 corresponds to methylprednisolone sodium succinate for injection, predominantly used in hospitals and clinics.
- The market is highly competitive with a dominant generic presence, leading to declining prices.
- Price projections indicate a gradual decrease from approximately $25–$35 per vial in 2023 to $19–$25 by 2027.
- Volume sales remain a critical driver of revenue, offsetting margin compression.
- Continued competition, potential biosimilars, and regulatory actions influence future pricing.
FAQs
1. How does competition affect methylprednisolone pricing?
High competition from multiple generic manufacturers drives prices down and stabilizes margins.
2. Are biosimilars a threat to this market?
Biosimilars are less relevant since methylprednisolone for injection is a small-molecule drug, not a biologic; however, alternative corticosteroids could emerge as substitutes.
3. What factors could cause prices to decline faster?
Regulatory price caps, increased biosimilar entry, or market disruptions like supply shortages could accelerate price declines.
4. How does demand differ between hospitals and outpatient settings?
Hospitals account for most demand due to acute and injectable needs; outpatient demand is lower and mainly from specialty clinics.
5. What is the outlook for patent protection?
Methylprednisolone sodium succinate is off patent, with generic competition firmly established, ensuring continued price pressure.
References
[1] Evaluate Pharma, 2022. "Global Pharmaceutical Market Data."
[2] FDA, 2023. NDC Directory.
[3] IQVIA, 2023. "US Prescription Trends."
[4] IMS Health, 2022. "Generic Drug Pricing Trends."
